PDF(Sci-hub)
Abstract：
OBJECTIVE: To measure the prevalence of vitamin D deficiency (through the 25-hydroxyvitamin D metabolite) in pediatric patients using antiepileptic drugs.
METHODS: Meta-analysis of studies identified through search in the PubMed, Embase, LILACS, and Cochrane Library databases, on February 19, 2019.
METHODS: A total of 748 articles were identified, 29 of which were relevant to the objectives of this study. The prevalence of vitamin D deficiency found was 0.32 (95% CI=0.25-0.41; I2=92%, p<0.01). In the subgroup analyses, the most significant results were observed in the group of patients using cytochrome P450-inducing antiepileptic drugs, with a prevalence of 0.33 (95% CI=0.21-0.47; I2=86%, p<0.01) and, considering the study design, in the subgroup of cohort studies, with a prevalence of 0.52 (95% CI=0.40-0.64; I2=76%, p<0.01).
CONCLUSIONS: Taking into account the deleterious effects of vitamin D deficiency on the bone health of individuals using antiepileptic drugs, it is suggested to include in their care 25-hydroxyvitamin D monitoring, cholecalciferol supplementation, and treatment of the deficiency, when present.
METHODS: Meta-analysis of studies identified through search in the PubMed, Embase, LILACS, and Cochrane Library databases, on February 19, 2019.
METHODS: A total of 748 articles were identified, 29 of which were relevant to the objectives of this study. The prevalence of vitamin D deficiency found was 0.32 (95% CI=0.25-0.41; I2=92%, p<0.01). In the subgroup analyses, the most significant results were observed in the group of patients using cytochrome P450-inducing antiepileptic drugs, with a prevalence of 0.33 (95% CI=0.21-0.47; I2=86%, p<0.01) and, considering the study design, in the subgroup of cohort studies, with a prevalence of 0.52 (95% CI=0.40-0.64; I2=76%, p<0.01).
CONCLUSIONS: Taking into account the deleterious effects of vitamin D deficiency on the bone health of individuals using antiepileptic drugs, it is suggested to include in their care 25-hydroxyvitamin D monitoring, cholecalciferol supplementation, and treatment of the deficiency, when present.
摘要：
目的：测量使用抗癫痫药物的儿科患者维生素D缺乏（通过25-羟维生素D代谢物）的患病率。
方法：通过PubMed搜索确定的研究的荟萃分析，Embase,LILACS,和Cochrane图书馆数据库，2019年2月19日。
方法：共确定了748篇文章，其中29个与本研究的目标相关。发现维生素D缺乏的患病率为0.32（95％CI=0.25-0.41;I2=92％，p<0.01)。在亚组分析中，在使用细胞色素P450诱导抗癫痫药物的患者组中观察到最显著的结果，患病率为0.33(95%CI=0.21-0.47；I2=86%，p<0.01)和，考虑到研究设计，在队列研究的亚组中，患病率为0.52(95%CI=0.40-0.64；I2=76%，p<0.01)。
结论：考虑到维生素D缺乏对使用抗癫痫药物的个体骨骼健康的有害影响，建议在他们的护理中包括25-羟基维生素D监测，补充胆钙化醇，和治疗缺陷，当存在。
方法：通过PubMed搜索确定的研究的荟萃分析，Embase,LILACS,和Cochrane图书馆数据库，2019年2月19日。
方法：共确定了748篇文章，其中29个与本研究的目标相关。发现维生素D缺乏的患病率为0.32（95％CI=0.25-0.41;I2=92％，p<0.01)。在亚组分析中，在使用细胞色素P450诱导抗癫痫药物的患者组中观察到最显著的结果，患病率为0.33(95%CI=0.21-0.47；I2=86%，p<0.01)和，考虑到研究设计，在队列研究的亚组中，患病率为0.52(95%CI=0.40-0.64；I2=76%，p<0.01)。
结论：考虑到维生素D缺乏对使用抗癫痫药物的个体骨骼健康的有害影响，建议在他们的护理中包括25-羟基维生素D监测，补充胆钙化醇，和治疗缺陷，当存在。
